PUK29 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE SYMPTOM CHECKLIST IN URINARY INCONTINENCE  by Arnould, B et al.
A86 Abstracts
feeder study baseline). These changes were maintained or further
improved during the open-label extension, such that signiﬁcant
improvements (p < 0.001 vs. feeder study baseline) were
observed for darifenacin 7.5/15mg in the same eight KHQ
domains after a further 24 months of treatment. Darifenacin was
well tolerated and the overall long-term safety proﬁle was con-
sistent to that observed in the 12 week phase III studies. CON-
CLUSIONS: Darifenacin signiﬁcantly improves QoL in patients
with OAB, with improvements maintained for 2 years during
open-label treatment.
PUK29
DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE
SYMPTOM CHECKLIST IN URINARY INCONTINENCE
Arnould B1, Benmedjahed K2,Amarenco G3, Coloby P4, Grise P5,
Haab F6, Richard F7
1Mapi Values, Lyon, Rhone, France; 2Mapi Values, Lyon, France;
3Rothshild hospital, Paris, France; 4René Dubos Hospital, Pontoise,
France; 5CHU Charles Nicolle, Rouen, France; 6Ténon hospital, Paris,
France; 7Pitié Salpétrière Hospital, Paris, France
OBJECTIVE: To develop and validate a unique tool speciﬁc to
urinary incontinence (UI) symptoms covering all types of incon-
tinence among both men and women. METHODS: An Advisory
Committee (AC) of 5 urologists was set up, involved at all stages
of questionnaire development and validation. A test question-
naire was developed by AC with content validity being assessed
simultaneously on 3 men, 4 women suffering from UI and 3 clin-
icians. Clinicians were asked to comment items’ relevance and
comprehensiveness; patients completed the scale and were asked
to provide general comments regarding the scale and detailed
comments regarding each element. The scale was redrafted and
tested on 25 other patients. A longitudinal, multi-centre, anony-
mous, observational study was carried out to validate the scale.
The scale was administrated by 21 urologists to 258 stable
patients (206 UI sufferers and 52 not UI sufferers) until June 15th
2005. Patients ﬁlled in the scale, the ICIQ-SF and a diary twice
at one-week interval and clinicians completed a medical form at
baseline. RESULTS: The test scale contained 11 items covering
urge, SUI, dysuria and pollakiuria. After initial cognitive debrief-
ing and comments of patients and clinicians, 3 items were sig-
niﬁcantly modiﬁed. The pilot questionnaire still included 11
items. The validation study allowed assessing the internal con-
sistency reliability, the test-retest reliability and the clinical valid-
ity of the scores. CONCLUSION: For the ﬁrst time,
psychometric properties were established for a simple-to-use,
unique and UI speciﬁc symptom scale for men and women. This
new instrument could be helpful for use in everyday medical
practice and in clinical research.
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OBJECTIVES: The International Prostatic Symptom Score
(IPSS) evaluates the frequency of symptoms associated with
lower urinary tract symptoms (LUTS). An eighth question (q8)
evaluates the patient’s overall satisfaction dealing with his
urinary tract status but does not study in detail his bothersome-
ness. The SPI score (Symptom Problem Index) evaluates the
degree of discomfort associated with each question on the IPSS.
Our objective was to determine the relations between IPSS, SPI
and quality of life IPSS item (q8) scores. METHODS: A cohort
of 907 male patients with BPH has been monitoring by French
general practitioners. The IPSS and SPI self-administered ques-
tionnaires have been evaluated on the 722 patients with com-
plete data. Relationships between SPI, IPSS and q8 have been
investigated through the correlation between those scores and by
showing the individual answers dispersion of IPSS and SPI scores
when one was ﬁxed. RESULTS: The mean IPSS score was 12.6
+/- 6.4, the mean SPI score was 12.2 +/- 6.5. The correlation
coefﬁcient between the IPSS and SPI scores was 0.70 ; the scores
from the two rating scales showed a very high variability. Q8
was also weakly related to SPI (r = 0.56) and to IPSS (r = 0.57).
The response to the question on quality of life corresponded to
highly varying SPI and IPSS scores. CONCLUSIONS: IPSS and
SPI questionnaires do not collect the same information. One
scale cannot be replaced by another. Quality of life question of
the IPSS questionnaire isn’t enough to capture all the aspects of
bothersomeness explored by the SPI questionnaire. Among
patients suffering from LUTS, the joint use of the IPSS and SPI
seems appropriate.
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OBJECTIVE: Since stress incontinence episodes frequency is
highly related to maintenance or avoidance of activities causing
leakages, the additional beneﬁt of therapeutic options might be
difﬁcult to capture. Our objective was to develop a new speciﬁc
and sensitive endpoint to evaluate treatment effects in Stress
Urinary Incontinence (SUI) in clinical trials. METHODS: A com-
prehensive list of efforts provoking leakages was established
from a systematic literature review and 30 clinician interviews.
The list was updated according to comments collected during 8
semi-structured clinicians interviews. Clinicians were asked
about the relevance, comprehensiveness, and ability of the listed
activities to capture changes. They also reported how their
patients managed to control the risk of leakage. Twenty SUI
women were asked to assess the relevance, importance, and
applicability of each effort, to reword the list and to describe
with their own words how they control the risk of leakage. The
scale was ﬁnalised according to their comments. RESULTS: A
list of 72 daily life efforts provoking leakage was set from 15 UI
speciﬁc scales and 21 studies selected from the literature. The
clinician interviews allowed to group similar concepts and to
establish a shortlist containing the 15 most relevant efforts.
Answer choices covered the occurrence of leakage, and various
behaviour adaptation such as seeking help, taking precautions,
muscular control, and avoiding situations. After validation of
format, items, wording, and answer choices, by the patients, the
pilot scale was produced. CONCLUSION: This self-reported
scale allows SUI patients to accurately describe their control on
leakage risk in daily life efforts. This highly speciﬁc instrument
will allow clinicians to better assess the true impact of thera-
peutics on patients’ life, in both clinical research and clinical
practice. The scoring procedure and its properties will be
assessed in a speciﬁc validation study.
